Cover Image
市場調查報告書

Cosmo Pharmaceuticals S.p.A - 產品平台分析

Cosmo Pharmaceuticals S.p.A - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 192539
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
Cosmo Pharmaceuticals S.p.A - 產品平台分析 Cosmo Pharmaceuticals S.p.A - Product Pipeline Review - 2015
出版日期: 2015年09月09日 內容資訊: 英文 42 Pages
簡介

Cosmo Pharmaceuticals S.p.A 是總公司設在盧森堡的製藥企業,進行消化器官疾病治療藥的開發、製造、銷售。還有委託契約生產,醫藥品穩定性評估,製造工程評估,臨床試驗的試劑準備等服務。

本報告提供Cosmo Pharmaceuticals S.p.A的治療藥開發平台的現狀及各開發階段比較分析,各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

目錄

Cosmo Pharmaceuticals S.p.A 基本資料

  • Cosmo Pharmaceuticals S.p.A 概要
  • 主要資訊
  • 企業資料

Cosmo Pharmaceuticals S.p.A :R&D概要

  • 主要的治療範圍

Cosmo Pharmaceuticals S.p.A :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Cosmo Pharmaceuticals S.p.A :開發中產品概況

  • 後期階段產品開發中產品
    • 第Ⅲ相的產品/聯合治療模式
  • 在臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 處於初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
  • 開發階段不明的開發中產品
    • 開發階段不明的產品/聯合治療模式

Cosmo Pharmaceuticals S.p.A :藥物簡介

  • mesalamine ER
  • rifamycin
  • AS-101
  • budesonide ER
  • CB-0604
  • naloxone hydrochloride
  • CB-0112

Cosmo Pharmaceuticals S.p.A :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Cosmo Pharmaceuticals S.p.A :最新的開發平台資訊

Cosmo Pharmaceuticals S.p.A :開發暫停中的計劃

Cosmo Pharmaceuticals S.p.A :開發中止的產品

  • 開發中止的產品簡介

Cosmo Pharmaceuticals S.p.A :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07561CDB

Summary

Global Markets Direct's, 'Cosmo Pharmaceuticals S.p.A - Product Pipeline Review - 2015', provides an overview of the Cosmo Pharmaceuticals S.p.A's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cosmo Pharmaceuticals S.p.A's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cosmo Pharmaceuticals S.p.A including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cosmo Pharmaceuticals S.p.A's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cosmo Pharmaceuticals S.p.A's pipeline products

Reasons to buy

  • Evaluate Cosmo Pharmaceuticals S.p.A's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cosmo Pharmaceuticals S.p.A in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cosmo Pharmaceuticals S.p.A's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cosmo Pharmaceuticals S.p.A and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cosmo Pharmaceuticals S.p.A
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cosmo Pharmaceuticals S.p.A and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cosmo Pharmaceuticals S.p.A Snapshot
    • Cosmo Pharmaceuticals S.p.A Overview
    • Key Information
    • Key Facts
  • Cosmo Pharmaceuticals S.p.A - Research and Development Overview
    • Key Therapeutic Areas
  • Cosmo Pharmaceuticals S.p.A - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Cosmo Pharmaceuticals S.p.A - Pipeline Products Glance
    • Cosmo Pharmaceuticals S.p.A - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Cosmo Pharmaceuticals S.p.A - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Cosmo Pharmaceuticals S.p.A - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Cosmo Pharmaceuticals S.p.A - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Cosmo Pharmaceuticals S.p.A - Drug Profiles
    • mesalamine ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rifamycin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AS-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • budesonide ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-0604
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • naloxone hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-0112
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cosmo Pharmaceuticals S.p.A - Pipeline Analysis
    • Cosmo Pharmaceuticals S.p.A - Pipeline Products by Target
    • Cosmo Pharmaceuticals S.p.A - Pipeline Products by Route of Administration
    • Cosmo Pharmaceuticals S.p.A - Pipeline Products by Molecule Type
    • Cosmo Pharmaceuticals S.p.A - Pipeline Products by Mechanism of Action
  • Cosmo Pharmaceuticals S.p.A - Recent Pipeline Updates
  • Cosmo Pharmaceuticals S.p.A - Dormant Projects
  • Cosmo Pharmaceuticals S.p.A - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • mesalamine ER
  • Cosmo Pharmaceuticals S.p.A - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cosmo Pharmaceuticals S.p.A, Key Information
  • Cosmo Pharmaceuticals S.p.A, Key Facts
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Indication, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Stage of Development, 2015
  • Cosmo Pharmaceuticals S.p.A - Monotherapy Products in Pipeline, 2015
  • Cosmo Pharmaceuticals S.p.A - Partnered Products in Pipeline, 2015
  • Cosmo Pharmaceuticals S.p.A - Partnered Products/ Combination Treatment Modalities, 2015
  • Cosmo Pharmaceuticals S.p.A - Out-Licensed Products in Pipeline, 2015
  • Cosmo Pharmaceuticals S.p.A - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Cosmo Pharmaceuticals S.p.A - Phase III, 2015
  • Cosmo Pharmaceuticals S.p.A - Phase II, 2015
  • Cosmo Pharmaceuticals S.p.A - Phase I, 2015
  • Cosmo Pharmaceuticals S.p.A - Preclinical, 2015
  • Cosmo Pharmaceuticals S.p.A - Unknown, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Target, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Route of Administration, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Molecule Type, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline Products by Mechanism of Action, 2015
  • Cosmo Pharmaceuticals S.p.A - Recent Pipeline Updates, 2015
  • Cosmo Pharmaceuticals S.p.A - Dormant Developmental Projects,2015
  • Cosmo Pharmaceuticals S.p.A - Discontinued Pipeline Products, 2015
  • Cosmo Pharmaceuticals S.p.A, Subsidiaries

List of Figures

  • Cosmo Pharmaceuticals S.p.A - Pipeline by Top 10 Indication, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Stage of Development, 2015
  • Cosmo Pharmaceuticals S.p.A - Monotherapy Products in Pipeline, 2015
  • Cosmo Pharmaceuticals S.p.A - Partnered Products in Pipeline, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Top 10 Target, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Top 10 Route of Administration, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline by Top 10 Molecule Type, 2015
  • Cosmo Pharmaceuticals S.p.A - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top